PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
The aim of the current study is pharmacoeconomic evaluation of using combined drug Vesomni (controlled release tablets tamsulosin 0.4 mg + solifenacin 6 mg) for treatment of patients with storage symptoms associated with benign prostatic hyperplasia, who do not respond to first line tamsulosin thera...
Saved in:
Main Authors: | N. A. Avxentyev (Author), M. Yu. Frolov (Author) |
---|---|
Format: | Book |
Published: |
IRBIS LLC,
2016-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia
by: Dimitropoulos K, et al.
Published: (2015) -
Fixed and separate combination of solifenacin and tamsulosin in urinary disorders associated with benign prostatic hyperplasia: a choice based on price and value comparison
by: A. G. Tolkushin, et al.
Published: (2019) -
Pharmacoeconomics expediency of application of the combined preparation of Vezomni in comparison with a combination of Tamsulosin and Solifenacin in the form of monopreparations
by: S. K. Zyryanov, et al.
Published: (2018) -
Comparing monotherapy with tadalafil or tamsulosin in men with benign prostatic hyperplasia: A case-control study
by: Hayder Adnan Fawzi, et al.
Published: (2024) -
Combination therapy with Tamsulosin plus Dutasteride Versus Tamsulosin in Benign Prostatic Hyperplasia: a Systematic review & Meta-analysis
by: Behnam Amani, et al.
Published: (2023)